New Momentum counterfeiting software for drugmakers
California, USA-based New Momentum, the provider of Enterprise Brand Intelligence software, is now offering its anti-counterfeiting software to help pharmaceutical companies.
Stu Clifton, the firm's chief executive, said that, "according to the Center for Medicine in the Public Interest, worldwide counterfeit sales are increasing at about 13% annually - nearly twice the pace of legitimate pharmaceuticals - and could become a $75.0-billion industry by 2010. These counterfeits pose a significant threat to patient safety as well as eroding pharmaceutical manufacturers' revenues and brand. Our solution gives our clients the tools they need to quickly find the counterfeits and get them to cease operations."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze